Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of June 2025. The specific transaction occurred on June 26, 2025, and was executed through the corporate stockbroker, Merrill Lynch International, pursuant to a non-discretionary agreement entered into on June 4, 2025.
Key Financial Metrics
The filing details a share repurchase program rather than operational financial results. Key metrics for the transaction on June 26, 2025, include:
- Shares Purchased: 485,032 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,390.00p; highest price paid was 1,405.00p.
- Average Price: Volume-weighted average price paid was 1,397.83p.
- Trading Venue: All purchases were executed on the London Stock Exchange (XLON).
Since the commencement of the current buyback agreement on June 4, 2025, the Company has purchased an aggregate of 7,072,240 ordinary shares.
Material Changes and Capital Structure
Following the June 26, 2025 purchase, the Company's capital structure reflects the following:
- Treasury Shares: The Company now holds 225,206,623 ordinary shares in treasury.
- Shares in Issue: There are 4,090,138,849 ordinary shares in issue (excluding Treasury shares).
- Voting Rights: The total number of voting rights is 4,090,138,849.
- Treasury Voting Percentage: The percentage of voting rights attributable to shares held in treasury is 5.51%.
The filing does not provide data on revenue, profit, cash flow, margins, or debt levels, as it is a disclosure of a specific share transaction.
Guidance, Outlook, and Risks
The filing contains no new operational guidance, outlook, or management commentary regarding business performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and its Q1 Results for 2025.
Important Facts for Investors to Verify
- Confirm the total remaining authorization under the existing buyback programme to assess future repurchase capacity.
- Verify the impact of the 5.51% treasury share holding on earnings per share (EPS) calculations and voting thresholds.
- Review the referenced 2024 Form 20-F and 2025 Q1 Results for the specific risk factors mentioned in the cautionary statement.
- Monitor subsequent Form 6-K filings to track the progress of the buyback programme initiated on June 4, 2025.